Skip to content

Acne Treatment with topical gel azithromycin 2%

azithromycin gel 2% in comparison with clindamycin gel 1% in acne vulgaris

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014031216970N1
Enrollment
40
Registered
2014-11-21
Start date
2013-11-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris. Acne vulgaris

Interventions

Intervention 1: Intervention group 1 =the use of gel azithromycin 2% on half of the face 2 times a day for 2 months. Intervention 2: Intervention Group 2 (Control )=the use of gel clindamycin 1% on ha
Treatment - Drugs
Intervention group 1 =the use of gel azithromycin 2% on half of the face 2 times a day for 2 months
Intervention Group 2 (Control )=the use of gel clindamycin 1% on half of the face 2 times a day for 2 months

Sponsors

VICE CHANCELLOR FOR RESEARCH OF ISFAHAN UNIVERSITY OF MEDICAL SCIENCES
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with mild and moderate FDA acne grading system scale , aged 12 to 45 years, both sexes, written informed consent for participation in the study , not receiving topical antibiotics within two weeks and systemic medications that are effective in acne within a month prior to the study, no history of hypersensitivity to any of the studies medications. Exclusion criteria: pregnancy or lactation, medical allergy or side effects, non- cooperation or lack of satisfactory treatment, the need for systemic medication during the study or concomitant use of drugs affecting acne

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of Acne. Timepoint: Beginning of the study design, 4th and 8th weeks of the treatment and 2 months after treatment. Method of measurement: Total count of lesions= TLC and acne severity index = ASI.;Patient satisfaction. Timepoint: 4th and 8th weeks of treatment and 2 months after treatment. Method of measurement: Scale of 10 ratings.

Secondary

MeasureTime frame
Burning and itching. Timepoint: 4th and 8th weeks of treatment and 2 months after treatment. Method of measurement: A scale of 4 ratings.;Erythema. Timepoint: 4th and 8th weeks of treatment and 2 months after treatment. Method of measurement: A scale of 4 ratings.;Dry. Timepoint: 4th and 8th weeks of treatment and two months after treatment. Method of measurement: A scale of 4 ratings.;Desquamation and peeling. Timepoint: 4th and 8th weeks of treatment and 2 months after treatment. Method of measurement: A scale of 4 ratings.;Recurrence. Timepoint: 2 months after treatment. Method of measurement: index of severity of acne=ASI Total lesion count = TLC.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDR. AKRAM BASIRI

ISFAHAN UNIVERSITY OF MEDICAL SCIENCES-DEPARTMENT OF DERMATOLOGY

akram basiri@med.mui.ac.ir ; AB13533@yahoo.com+98 31 3267 0694

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026